Adhérent PreciDIAB : StarkAge Therapeutics

StarkAge Therapeutics is a privately-held, early-stage biotechnology company and pioneer in the field of senescence. Based in France in Lille, it was founded in 2018 by Dr. Thierry Mathieu on the idea that the elimination by targeted immunotherapy of senescent cells specific to certain age-related diseases could bring significant therapeutic benefits to patients. Initially, we focus on pulmonary fibrosis and hepatic fibrosis (NASH/NAFLD)

Joining the PreciDIAB club was obvious for a young start-up like ours. Being able to discuss with academic and industrial experts, and share our experiences and knowledge, is a major source of mutual enrichment.